Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Howell

Showing results (231-240 of 260) with videos related to

Pageof 26
Sort By:
British Journal of Cancer|June 9, 1999
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatinB Cenni, H K Kim, G J Bubley, et al.
Investigational New Drugs|December 16, 1998
Phase I and pharmacokinetic study of intraperitoneal topotecanS C Plaxe, R D Christen, J O'Quigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancerK T Robbins, A M Storniolo, C Kerber, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinomaE F McClay, P D Braly, S Kirmani, et al.
Cancer|March 1, 1997
A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanomaE F McClay, M E McClay, J A Jones, et al.
Cancer Research|August 1, 1997
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatinA Nehmé, R Baskaran, S Aebi, et al.
British Journal of Cancer|September 1, 1995
Enhancement of drug sensitivity of human malignancies by epidermal growth factorR Kröning, J A Jones, D K Hom, et al.
Cancer|September 15, 1993
Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observationE F Mc Clay, M E Mc Clay, K D Albright, et al.
The Journal of Clinical Investigation|October 1, 1992
Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alphaS Isonishi, A P Jekunen, D K Hom, et al.
Gynecologic Oncology|October 1, 1993
Phase I and pharmacokinetic study of intraperitoneal ormaplatinS C Plaxe, P S Braly, J L Freddo, et al.
Pageof 26

Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
British Journal of Cancer|June 9, 1999
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatinB Cenni, H K Kim, G J Bubley, et al.
Investigational New Drugs|December 16, 1998
Phase I and pharmacokinetic study of intraperitoneal topotecanS C Plaxe, R D Christen, J O'Quigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancerK T Robbins, A M Storniolo, C Kerber, et al.
American Journal of Clinical Oncology|February 1, 1995
A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinomaE F McClay, P D Braly, S Kirmani, et al.
Cancer|March 1, 1997
A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanomaE F McClay, M E McClay, J A Jones, et al.
Cancer Research|August 1, 1997
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatinA Nehmé, R Baskaran, S Aebi, et al.
British Journal of Cancer|September 1, 1995
Enhancement of drug sensitivity of human malignancies by epidermal growth factorR Kröning, J A Jones, D K Hom, et al.
Cancer|September 15, 1993
Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observationE F Mc Clay, M E Mc Clay, K D Albright, et al.
The Journal of Clinical Investigation|October 1, 1992
Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alphaS Isonishi, A P Jekunen, D K Hom, et al.
Gynecologic Oncology|October 1, 1993
Phase I and pharmacokinetic study of intraperitoneal ormaplatinS C Plaxe, P S Braly, J L Freddo, et al.
Pageof 26